An Incidental FIB-4 Result: Check the Framework Before the Category

Quick Medical Calculator · Reading label 17 September 2026 · 3 min read

Retrospective study sequence, not publication date

Retrospective educational series: 17 September to 16 October 2026. This coverage window is not the publication date.

A FIB-4 result can help organise further liver assessment. It cannot tell you that a person has a particular histological fibrosis stage. Before interpreting an incidental result, establish why it was calculated and which population-specific pathway is being used.

Work Through the Actual Inputs

Consider a fictional, clinically stable 52-year-old undergoing assessment for suspected metabolic liver disease. AST is 40 U/L, ALT 64 U/L and platelets 160 x 10^9/L. These are teaching values, not a patient record.

FIB-4 = age x AST / (platelets x square root of ALT).

Here, square root of 64 is 8. The numerator is 52 x 40 = 2,080; the denominator is 160 x 8 = 1,280. FIB-4 is therefore 1.625. The local tool displays 1.6250; rounded to two decimal places it is 1.63. Enter 160 for the platelet input in this unit convention, not 160,000.

In the AASLD 2023 NAFLD practice guidance, that result is in a range requiring secondary assessment rather than reassurance from the initial test alone. The source predates the MASLD terminology; its original disease name identifies the guidance, rather than claiming that all later definitions are identical. The result is not a probability of cirrhosis or a diagnosis of advanced fibrosis. The guidance also gives different considerations above age 65, notes reduced accuracy below age 35 and advises against use during acute illness. This article describes that framework, not every later liver guideline or a treatment pathway. AASLD guidance.

Age Can Change the Number Without a Laboratory Change

Keep all three laboratory values identical but substitute age 72. The arithmetic becomes 72 x 40 / 1,280 = 2.25. In this example, both people fall within the local tool's secondary-assessment range, despite their different scores and age-adjusted assessment thresholds. The larger number alone does not establish a worse fibrosis stage in the older person. Age is an input, not a measurement of liver scarring.

This counterexample is useful when reviewing an automated laboratory comment. A categorical label may look more definitive than the underlying calculation. Read the age, clinical indication and selected interpretation framework together.

Make the Handover Actionable

Record the actual inputs and specimen dates, whether the person was stable, and the framework used. Note any reason platelets or aminotransferases might not reflect chronic liver disease. Then document who will arrange and interpret the next assessment, rather than writing only "FIB-4 elevated".

The FIB-4 calculator offers metabolic-liver and historical HIV/HCV interpretation options. Those are different frameworks, not interchangeable risk labels. Do not select the framework that produces the most reassuring category.

Checkpoint: Does a FIB-4 of 1.63 establish stage F2? No. It identifies a need to interpret an initial non-invasive assessment within a defined pathway. The next clinical question is what further assessment is appropriate, not which fibrosis stage to copy into the record.

Source scope: relevant guidance body and Figure 2 restrictions checked; current local pathway and subsequent guidance must be checked during clinical review. No treatment recommendation or individual prognosis is supplied.